113 related articles for article (PubMed ID: 36502926)
1. Medullary carcinoma of the ampulla has distinct clinicopathologic characteristics including common association with microsatellite instability and PD-L1 expression.
Xue Y; Balci S; Pehlivanoglu B; Muraki T; Memis B; Saka B; Kim G; Bandyopadhyay S; Knight J; El-Rayes B; Kooby D; Maithel SK; Sarmiento J; Basturk O; Reid MD; Adsay V
Hum Pathol; 2023 Jan; 131():38-46. PubMed ID: 36502926
[TBL] [Abstract][Full Text] [Related]
2. Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated.
Xue Y; Balci S; Aydin Mericoz C; Taskin OC; Jiang H; Pehlivanoglu B; Muraki T; Memis B; Saka B; Kim GE; Bandopadhyay S; Knight J; El-Rayes BF; Sarmiento J; Reid MD; Erkan M; Basturk O; Adsay V
Cancer; 2020 Nov; 126(21):4788-4799. PubMed ID: 32857459
[TBL] [Abstract][Full Text] [Related]
3. Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.
Xue Y; Vanoli A; Balci S; Reid MM; Saka B; Bagci P; Memis B; Choi H; Ohike N; Tajiri T; Muraki T; Quigley B; El-Rayes BF; Shaib W; Kooby D; Sarmiento J; Maithel SK; Knight JH; Goodman M; Krasinskas AM; Adsay V
Mod Pathol; 2017 Feb; 30(2):255-266. PubMed ID: 27739441
[TBL] [Abstract][Full Text] [Related]
4. Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases.
Adsay V; Ohike N; Tajiri T; Kim GE; Krasinskas A; Balci S; Bagci P; Basturk O; Bandyopadhyay S; Jang KT; Kooby DA; Maithel SK; Sarmiento J; Staley CA; Gonzalez RS; Kong SY; Goodman M
Am J Surg Pathol; 2012 Nov; 36(11):1592-608. PubMed ID: 23026934
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.
Saraggi D; Galuppini F; Remo A; Urso EDL; Bacchin D; Salmaso R; Lanza C; Bao RQ; Fanelli GN; Guzzardo V; Luchini C; Scarpa M; Farinati F; Fassan M; Rugge M
Histopathology; 2017 Sep; 71(3):470-474. PubMed ID: 28502094
[TBL] [Abstract][Full Text] [Related]
6. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
[TBL] [Abstract][Full Text] [Related]
8. Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases.
Ohike N; Kim GE; Tajiri T; Krasinskas A; Basturk O; Coban I; Bandyopadhyay S; Morohoshi T; Goodman M; Kooby DA; Sarmiento JM; Adsay NV
Am J Surg Pathol; 2010 Dec; 34(12):1731-48. PubMed ID: 21084962
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
Ruemmele P; Dietmaier W; Terracciano L; Tornillo L; Bataille F; Kaiser A; Wuensch PH; Heinmoeller E; Homayounfar K; Luettges J; Kloeppel G; Sessa F; Edmonston TB; Schneider-Stock R; Klinkhammer-Schalke M; Pauer A; Schick S; Hofstaedter F; Baumhoer D; Hartmann A
Am J Surg Pathol; 2009 May; 33(5):691-704. PubMed ID: 19252434
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Int J Gynecol Pathol; 2021 Nov; 40(6):563-574. PubMed ID: 33323859
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Guazzo E; Cooper C; Wilkinson L; Feng S; King B; Simpson F; Porceddu S; Panizza B; Coward JIG
Head Neck; 2021 Mar; 43(3):768-777. PubMed ID: 33169486
[TBL] [Abstract][Full Text] [Related]
12. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
15. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
16. DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases.
Agaram NP; Shia J; Tang LH; Klimstra DS
Am J Clin Pathol; 2010 May; 133(5):772-80. PubMed ID: 20395525
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma.
Yamashita S; Abe H; Yamashita H; Yagi K; Seto Y; Ushiku T
Histopathology; 2023 Aug; 83(2):264-275. PubMed ID: 37071391
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
20. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
